Abstract | INTRODUCTION: Modern therapy makes it possible for 60-80% patients with acute myeloid leukemia to achieve complete remission after induction therapy. However, most of them will relapse within six months to a year without additional cytostatic therapy. The questions regarding post-remission therapy remain unanswered. The objective of this study was to compare the survival and relapse rate among the patients who had received high dose cytosine-arabinoside during consolidation therapy and the patients who had not received high dose cytosine-arabinoside during consolidation therapy. MATERIAL AND METHODS: The study included 59 patients aged 18-60 years with de novo acute myeloid leukemia (except for Acute promyelocytic leukemia, which was excluded according to the French-American-British classification) who achieved complete remission. Thirty-nine patients who received high dose cytosine-arabinoside during consolidation were included in the study group and twenty patients who did not receive high dose cytosine-arabinoside during consolidation were in the control group. RESULTS: CONCLUSION:
|
Authors | Vanja Zeremski, Aleksandar Savić |
Journal | Medicinski pregled
(Med Pregl)
2014 Mar-Apr
Vol. 67
Issue 3-4
Pg. 83-90
ISSN: 0025-8105 [Print] Serbia |
PMID | 24961049
(Publication Type: Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Cytarabine
|
Topics |
- Adolescent
- Adult
- Antimetabolites, Antineoplastic
(therapeutic use)
- Consolidation Chemotherapy
- Cytarabine
(administration & dosage)
- Female
- Humans
- Leukemia, Myeloid, Acute
(drug therapy, mortality)
- Male
- Middle Aged
- Recurrence
- Remission Induction
- Survival Rate
- Young Adult
|